Results of the POET-COPD® Study
The results of the POET-COPD®study, which involved 7376 patients with moderate to severe COPD and a history of exacerbations, show that Spiriva® significantly delayed the occurrence of the first COPD exacerbation. A 17 percent overall risk reduction (p
COPD Exacerbations
COPD exacerbations (sometimes referred to as COPD lung attacks) are an acute worsening of COPD symptoms and have a severe impact on patients' health. Frequent exacerbations indicate a deterioration and progression of the disease.2,3,4 They are associated with a more rapid decline in lung function over time and, in severe cases, an increased risk of mortality, and they can severely compromise patients' health-related quality of life.2,3,4 Economic analyses suggest that hospitalisation due to COPD exacerbations accounts for 40-70 percent of all medical expenses for patients with COPD.9,10,11,12The cost of hospitalisation for COPD patients is estimated at $6.1 billion in the U.S.A. alone.12As hospitalisation accounts for the largest component of cost in the management of COPD, interventions reducing hospitalisation will have the greatest impact on the cost of treating COPD for all severities of the disease.9
The POET-COPD® study was a one-year, randomised, double-blind, double-dummy, parallel-group trial involving 7376 patients with moderate to severe COPD from 25 countries in 725 centres.1 The study was specifically designed to compare the effects on exacerbations of two long-acting bronchodilators; both are recommended as maintenance therapy of COPD by international guidelines and are widely used.13,14
"COPD exacerbations can occur even in the early stages of COPD (e.g. GOLD Stage II) and may recur throughout the course of the disease. They are associated with substantial personal, medical, societal and economic burden. Prevention of exacerbations constitutes a major treatment goal and is a key concern for COPD patients," said Professor Dr. Klaus Rabe, Department of Medicine, University of Kiel and Grosshansdorf Hospital, Germany. "The results of the POET-COPD® study, comparing two long-acting bronchodilators, should help to guide clinical practice in the management of COPD and the prevention of exacerbations."
* Via HandiHaler®
** Via HFA (metered-dose inhaler)
*** Global Initiative for Chronic Obstructive Lung Disease
Notes
About COPD
Chronic Obstructive Pulmonary Disease (COPD) is a progressive yet treatable disease that restricts patients' lives over time and is a major cause of death and disability throughout the world. Symptoms include cough, sputum (mucus or phlegm) production, and breathlessness on exertion. Acute worsening of these symptoms, i.e. exacerbations (sometimes referred to as COPD lung attacks due to their severe impact on patients' health) often occur and can restrict a patient's ability to perform normal daily activities.13 The latest World Health Organization (WHO) figures estimate that 210 million people are currently living with COPD and more than 3 million people died from the disease in 200515- more than breast cancer and diabetes combined.16Dyspnoea (breathlessness), the main symptom of COPD, is characteristically persistent and progressive and has a serious impact on patients' quality of life.13 At its most severe, it even limits a patient from performing simple tasks such as washing and dressing.
About the POET-COPD®Study
The Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD®) study was a one-year, multicentre (725 sites), multinational (25 countries), randomised, double-blind, double-dummy, parallel-group trial which included 7376 male and female COPD patients. The primary objective of this study was to compare the effect of Spiriva® (18 ?µg) inhalation capsule via HandiHaler® and salmeterol (50 ?µg) via HFA metered dose inhaler (MDI) on COPD exacerbations.1
Patients included in the trial had to be ?‰?40 years of age, have a smoking history of ?‰?10 pack-years and a diagnosis of moderate to very severe COPD with a history of at least one exacerbation within the previous year requiring treatment with either systemic steroids and/or antibiotics or hospitalisation.1
About Spiriva® (tiotropium)
Spiriva®, a long-acting inhaled anticholinergic medication, is the first inhaled treatment to provide significant and sustained improvements in lung function with once-daily dosing. Spiriva® positively impacts the clinical course of COPD, helping to change the way patients live with their disease.17,18It is the most prescribed maintenance therapy for COPD worldwide. Spiriva® helps COPD patients breathe easier by opening narrowed airways and helping to keep them open for 24 hours. Spiriva® works through targeting of a dominant reversible mechanism of COPD - cholinergic bronchoconstriction.
Spiriva® has demonstrated significant and sustained bronchodilation (opening of the airways)19and reduction in hyperinflation (air trapping).20,21 In placebo-controlled studies, patients treated with Spiriva® had less activity-induced breathlessness and improved exercise endurance.17In the UPLIFT® trial, Spiriva® demonstrated proven benefits for up to four years including improved lung function and quality of life as well as reduced exacerbations and COPD-related hospitalisations.22****These benefits were shown in a broad range of COPD severities, including patients with early-stage COPD (GOLD Stage II),23*patients new to maintenance therapy,24 * and younger patients (
Our Recommendations:
• Purchase Hydrochlorothiazide
• Buy Generic Suprax Without Prescription
• Buy Cheap Sterapred
No hay comentarios:
Publicar un comentario